Why FDA Removed The Black Box Warning For Menopausal Hormone Therapy

The FDA has lifted the black box warning on menopausal hormone therapy (MHT) which previously cautioned against a higher risk of heart disease, stroke, and breast cancer. This decision is based on new evidence suggesting the risks associated with hormone therapy vary depending on the individual’s age, health status, and the timing of therapy initiation.

Research has shown that for women who begin hormone therapy close to menopause, the benefits can outweigh the risks, particularly in improving symptoms like hot flashes and night sweats. Consequently, the revision aims to reflect a more nuanced understanding of hormone therapy and its implications for different populations.

This change is intended to provide healthcare providers and patients with clearer information, allowing for more informed decisions regarding menopausal treatment options. The FDA emphasizes the importance of a personalized approach in managing menopause and suggests discussing the potential benefits and risks with a healthcare professional.

WWII nurses who dodged bullets and saved lives deserve Congressional honor, lawmakers say

A coalition of retired military nurses and advocates is urging Congress to award the Congressional Gold Medal to nurses who served during World War II. These nurses played a critical role on the battlefield, often risking their lives to provide medical care to soldiers. Many of them faced dangerous conditions, with some even being captured as prisoners of war or killed by enemy fire.

At the forefront of this initiative is 106-year-old Alice Darrow, who recalls her experiences as a wartime nurse. She emphasizes the profound impact that nurses have had in every war, often without receiving the recognition they deserve. The coalition highlights the urgency of honoring these nurses, as the number of living WWII nurses is dwindling, with only a few remaining today.

Legislation has been introduced in Congress by Senator Tammy Baldwin and Representative Elise Stefanik to confer this honor. However, the legislation faces challenges, as it requires significant support from both the Senate and the House to move forward. Advocates believe it is crucial to acknowledge the sacrifices and contributions of WWII nurses to ensure their legacy is remembered.

AI's Impact on Social Psychology: Ethical Guardrails Matter

Artificial Intelligence (AI) is significantly changing social behavior and dynamics, often undermining individual autonomy. The increasing convenience of technology can lead to manipulation, where users feel compelled to consent to practices that infringe on their privacy. This situation highlights the need for strong ethical safeguards to protect personal agency and the integrity of human connections.

The article emphasizes that while we cannot reverse the advancements in technology, new ethical guidelines are necessary as AI becomes deeply integrated into various sectors like healthcare, education, and commerce. This integration has transformed how consumers experience technology, forcing them into situations where they must consent to data practices without true understanding or choice.

The impact of forced consent has serious psychological implications, contributing to stress, anxiety, and feelings of helplessness. Many individuals feel they lack the freedom to protect their privacy, leading to a conflict between the desire for connection and the push to conform to technology's demands. Over time, reliance on AI can erode personal agency, manipulate behaviors, and restrict the ability to make independent choices, thereby reshaping society itself.

Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends

Yahoo is part of a brand group that includes various websites and apps such as Yahoo, AOL, Engadget, In The Know, and Makers.

When using these websites and apps, Yahoo employs cookies and similar technologies to store and read information from your device. This helps in services like user authentication, security measures, and preventing spam.

Yahoo collects aggregated data about visitors, including the type of device and browser used, along with the duration of visits. This information is used to assess how users interact with their products.

Users have the option to consent to or reject cookies and data usage for personalized ads and analytics. Preferences can be managed anytime through links for privacy and cookie settings available on their platforms. More information on how personal data is used can be found in their privacy and cookie policies.

Dr. Christina Rahm Wins Two Silver Stevie® Awards at the 2025 Stevie Awards for Women in Business

Dr. Christina Rahm has received two Silver Stevie® Awards at the 2025 Stevie Awards for Women in Business. She was recognized as the Female Thought Leader of the Year in Consumer Products and the Most Innovative Woman of the Year in Manufacturing. The awards honor women's achievements in leadership and entrepreneurship globally.

Dr. Rahm is the co-founder of The ROOT Brands and emphasizes innovation in biotechnology and sustainability. Alongside her husband, she has successfully expanded their company into over 90 countries, offering wellness products aimed at detoxifying and rejuvenating health. She believes these awards reflect a shared mission to improve global health and well-being.

Having overcome personal health challenges, including Lyme disease and cancer, Dr. Rahm advocates for education and environmental sustainability through her book, "Cure the Causes," and her nonprofit, The Rahm Foundation. Her work demonstrates the powerful impact of women in leadership roles.

In addition to her multiple roles, Dr. Rahm leads over 20 companies and holds seven approved patents. The Stevie® Awards celebrate exceptional accomplishments and innovation across various industries, with thousands of entries from around the world each year.

Woman's First Sign of Breast Cancer Was 'Pink Eye' Before Diagnosis at 35

Kelly Mann, a 35-year-old woman from Abilene, Texas, was diagnosed with Stage 2 breast cancer over two years ago. She experienced a puzzling eye issue, initially interpreting it as severe pink eye. This condition recurred several times between April and June, eventually leading her to discover a lump in her breast while watching TV.

After confirming the lump with a doctor, Mann received her diagnosis just a week before her 36th birthday. She was devastated to learn that her tumor had quickly grown in size, despite a previous well-woman exam that had shown no abnormalities.

Mann's unusual first symptom, the redness in her eyes, was identified as episcleritis, an inflammation that can sometimes be connected to other health conditions, including cancer. This experience highlighted the complex ways in which the body can signal health issues. Throughout her treatment, Mann learned to manage her symptoms with steroid eye drops.

FDA removing warning from hormone-based menopause drugs

The U.S. Food and Drug Administration (FDA) has decided to remove a long-standing safety warning that was associated with hormone-based treatments for menopause. This change comes after new research suggested the risks previously outlined may not be as significant as once thought.

Previously, the FDA had raised concerns about the possible increased risk of certain health issues linked to these hormone therapies, particularly regarding breast cancer and cardiovascular problems. However, studies conducted since then indicate that these risks might not be as relevant for many women using the treatments.

This update aims to provide clearer guidance and potentially encourage more women to consider hormone therapy for managing menopausal symptoms, which can significantly impact quality of life. The FDA emphasizes that women should consult their healthcare providers to make informed decisions based on their individual health profiles.

Experts say 3 simple daily habits could slash your Diabetes risk by 31% — here’s how

Experts suggest that adopting three simple daily habits can reduce the risk of developing type 2 diabetes by 31%. These habits include following a Mediterranean diet, cutting daily calorie intake, and engaging in regular moderate physical activity. Such lifestyle changes can also assist in weight management and promote overall health.

According to the CDC, type 2 diabetes is prevalent, with one in ten Americans affected, but many cases are preventable through lifestyle adjustments. A study published in the Annals of Internal Medicine analyzed nearly 5,000 overweight adults aged 55 to 75 with metabolic syndrome. The participants who made lifestyle changes, including calorie reduction and exercise, significantly lowered their diabetes risk compared to those who only followed a Mediterranean diet.

The Mediterranean diet is rich in fiber, healthy fats, and low in sugar and processed foods, contributing to its health benefits. Moderate physical activity, such as brisk walking and strength training, is essential and should elevate the heart rate without causing breathlessness. For calorie control, experts recommend gradually reducing calorie intake and choosing healthier food options, which can aid in weight loss and blood sugar control.

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon has agreed to sell its JADA® System to Laborie Medical Technologies for a total of up to $465 million. The deal involves an upfront payment of $440 million, with an additional potential payment of $25 million based on revenue targets for 2026. The transaction is expected to lead to the transfer of approximately 100 Organon employees to Laborie.

The proceeds from this sale will be used by Organon to reduce its debt, aligning with its goal of improving its financial position. This divestment allows Organon to focus its investments on growth opportunities, particularly in the field of women’s health biopharma and other strategic areas.

Laborie, known for its medical technology capabilities, aims to enhance access to the JADA System for mothers worldwide, building on its legacy of supporting health solutions for new mothers in over 20 countries.

Preconception care uptake and risk factors for adverse pregnancy outcomes among pregnant women in Tigray, northern Ethiopia: A community-based cross-sectional study

Adverse pregnancy outcomes are a significant public health issue, particularly in low- and middle-income countries. This study focuses on the uptake of preconception care (PCC) among pregnant women in Tigray, Ethiopia, where these outcomes are notably high due to various factors, including the impact of conflict.

The research involved 764 pregnant women in their first or second trimester from July 31 to August 16, 2024. Data were collected through questionnaires, measuring the use of PCC services, which include screening, counseling, and management. The findings revealed that only 7.2% of women accessed PCC services, highlighting an alarming gap in care.

All participants faced at least one risk factor for adverse pregnancy outcomes. Factors positively associated with the uptake of PCC included women's decision-making power, knowledge about PCC, HIV screening during pregnancy, and awareness of preconception risks. To improve PCC uptake, the study suggests a comprehensive strategy combining public health campaigns, enhanced health programs, and the use of reproductive planning tools.